Trials / Recruiting
RecruitingNCT07275788
A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
An Exploratory Study of REGEND003 Kidney Progenitor Cells on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Regend Therapeutics · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGEND003 | REGEND003 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2026-01-08
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-12-10
- Last updated
- 2026-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07275788. Inclusion in this directory is not an endorsement.